Hoechst Pakistan Limited
(Formerly Sanofi-Aventis Pakistan Limited)
Plot No. 23, Sector 22,
Korangi Industrial Area,
Karachi 74900, Pakistan

Ref: Fin-0044/2026 **FORM-7**

August 20, 2026

The General Manager
Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi -74000.

SUBJECT: FINANCIAL RESULTS FOR THE HALF YEAR ENDED JUNE 30, 2026

Dear Sir

We are pleased to inform you that the Board of Directors of Hoechst Pakistan Limited (the Company) in its meeting held on Thursday, August 20, 2026 at 11:00 a.m. at Head Office of the Company and through video link arrangement has approved the condensed interim financial statements (un-audited) of the Company for the half year ended June 30, 2026 and recommended the following:

(i) **CASH DIVIDEND:**

An interim cash dividend for the half year ended June 30, 2026, at Rs. 80/- per share i.e. 800%.

(ii) **BONUS SHARES:**

Nil

(iii) **RIGHT SHARES:**

Nil

(iv) **ANY OTHER ENTITLEMENT / CORPORATE ACTION:**

Nil

(v) **ANY OTHER PRICE-SENSITIVE INFORMATION:**

Disclosure of Material Information – Evaluation of strategic expansion options

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Rule Book issued by the Pakistan Stock Exchange Limited ("PSX"), Hoechst Pakistan Limited (the "Company") hereby conveys the following information:

This is further to our letter dated March 24, 2026 through which we communicated that the Board of Directors of the Company accorded its in-principle approval to the management to evaluate various options for medium-long term strategic expansion of the Company including potential product partnerships, investment into manufacturing assets and acquisition of majority stake in pharmaceutical company either directly or through its subsidiary company(ies).

Hoechst Pakistan Limited
(Formerly Sanofi-Aventis Pakistan Limited)
Plot No. 23, Sector 22,
Korangi Industrial Area,
Karachi 74900, Pakistan

With this background, please note that the Board of Directors of the Company, in its meeting held on August 20, 2026 has authorized the management to conclude due diligence for the potential acquisition of a pharmaceutical company and to finalize commercial terms and conditions including binding offer(s) and definitive agreement(s) subject to compliance with the applicable laws and fulfillment of applicable corporate and regulatory approvals.

The said disclosure form as required under S.R.O. 143/(1)/2012 dated December 05, 2012 read with Sections 96 and 131 of the Securities Act, 2015 is also enclosed as **Annexure C** hereto.

The financial results of the Company for the captioned period are enclosed as **Annexure 'A1 to A5'** (Unconsolidated) and **Annexure 'B1 to B5'** (Consolidated) to this letter.

The above entitlement of interim cash dividend will be paid to the shareholders whose names will appear in the Register of Members (with their updated IBAN details) on Wednesday, September 02, 2026.

The Share Transfer Books of the Company will be closed from Thursday, September 03, 2026 to Friday, September 04, 2026 (both days inclusive). Transfers received at the office of the Company's Share Registrar, M/s FAMCO Share Registration Services (Pvt.) Limited, 8-F, near Hotel Faran, Nursery, Block 6, P.E.C.H.S., Shahrah-e-Faisal, Karachi at the close of business on Wednesday, September 02, 2026, or updated on Central Depository System as per CDC regulations, will be treated in time for the purpose of above entitlement to the transferees.

The Half Yearly Report of the Company for the half year ended June 30, 2026 will be transmitted through PUCARS separately, within the specified time and shall also be made available on Company's website www.hoechst.com.pk.

Yours sincerely

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Syed Muhammad Taha Naqvi
Company Secretary

Encl: As above.

Cc:

Director Company Law Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	**Director** Enforcement Department Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	**Director** Securities Market Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	**Executive Director / HOD** Offsite-II Department Supervision Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad

Annexure A-1

Hoechst Pakistan Limited

Unconsolidated Condensed Interim Statement of Profit or Loss

For the half year June 30, 2026 (Un-audited)

	Half Year Ended		Quarter Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	Rupees in '000			
REVENUE FROM CONTRACT WITH CUSTOMERS - NET	16,669,186	16,284,731	8,979,964	8,711,238
Cost of sales	(10,080,852)	(10,665,438)	(5,352,440)	(5,777,754)
GROSS PROFIT	6,588,334	5,619,293	3,627,524	2,933,484
Distribution and marketing costs	(2,701,961)	(2,272,869)	(1,438,689)	(1,169,254)
Administrative expenses	(541,469)	(511,946)	(258,163)	(242,682)
Reversal / (Allowance) for expected credit loss	11,259	(14,903)	53,305	31,563
Other expenses	(452,608)	(523,094)	(319,515)	(324,481)
Other income	852,905	107,574	771,236	63,517
	(2,831,874)	(3,215,238)	(1,191,826)	(1,641,337)
OPERATING PROFIT	3,756,460	2,404,055	2,435,698	1,292,147
Finance costs	(58,144)	(58,168)	(33,005)	(16,673)
PROFIT BEFORE LEVIES AND INCOME TAX	3,698,316	2,345,887	2,402,693	1,275,474
Levies:				
- Minimum tax differential	-	-	-	12,909
- Final tax	-	-	-	696
PROFIT BEFORE INCOME TAX	3,698,316	2,345,887	2,402,693	1,289,079
Income tax - Current	(1,352,985)	(937,681)	(647,091)	(475,623)
- Deferred	(149,730)	(64,261)	(280,553)	(23,118)
	(1,502,715)	(1,001,942)	(927,644)	(498,741)
PROFIT FOR THE PERIOD	2,195,601	1,343,945	1,475,049	790,338
EARNINGS PER SHARE - basic and diluted (Rupees)	227.65	139.34	152.94	81.94

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Annexure A-2

Hoechst Pakistan Limited

Unconsolidated Condensed Interim Statement of Comprehensive Income

For the half year June 30, 2026 (Un-audited)

	Half Year Ended		Quarter Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	Rupees in '000			
PROFIT FOR THE PERIOD	2,195,601	1,343,945	1,475,049	790,338
OTHER COMPREHENSIVE INCOME FOR THE PERIOD	-	-	-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	2,195,601	1,343,945	1,475,049	790,338

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Annexure A-3

Hoechst Pakistan Limited
Unconsolidated Condensed Interim Statement of Financial Position
As at June 30, 2026

	June 30, 2026	December 31, 2025
	---- Rupees in '000 ----	
	(Un-audited)	(Audited)
ASSETS		
NON-CURRENT ASSETS		
Property, plant and equipment	3,048,580	2,563,716
Intangible assets	805,278	806,053
Investment properties	27,129	27,714
Long-term investments	338,940	270,000
Long-term loans	9,502	8,464
Long-term deposits	57,245	66,493
Deferred tax asset - net	396,610	546,340
	4,683,284	4,288,780
CURRENT ASSETS		
Stores and spares	103,170	103,363
Stock-in-trade - net	5,669,787	6,617,315
Trade debts - net	501,036	798,679
Loans and advances	498,821	273,255
Trade deposits and short-term prepayments	568,853	258,581
Other receivables	108,171	81,358
Short-term investments	2,443,719	1,037,367
Income tax recoverable - net	703,619	907,473
Cash and bank balances	228,975	134,916
	10,826,151	10,212,307
TOTAL ASSETS	15,509,435	14,501,087
EQUITY AND LIABILITIES		
SHARE CAPITAL AND RESERVES		
Share capital	96,448	96,448
Reserves	8,469,829	8,106,732
	8,566,277	8,203,180
NON-CURRENT LIABILITIES		
Lease liability	390,271	208,109
Sindh Infrastructure Development Cess (SIDC)	363,789	-
	754,060	208,109
CURRENT LIABILITIES		
Trade and other payables	5,716,190	5,871,945
Contract liabilities	214,527	146,854
Current maturity of long term lease liability	82,405	53,364
Current maturity of SIDC	151,552	-
Unclaimed dividend	24,424	17,635
	6,189,098	6,089,798
CONTINGENCIES AND COMMITMENTS		
TOTAL EQUITY AND LIABILITIES	15,509,435	14,501,087

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Annexure A-4

Hoechst Pakistan Limited
Unconsolidated Condensed Interim Statement of Changes in Equity
For the half year June 30, 2026 (Un-audited)

	Issued, subscribed and paid-up share capital	Reserves							Total
		Capital Reserves				Revenue Reserves			
		Long-term liabilities forgone	Other capital reserve	Difference of share capital under scheme of arrangement for amalgamation	Share- based payments reserve	General reserve	Unappropriated profits		
	Rupees in '000								
Balance as at January 01, 2025 (Audited)	96,448	5,935	2,000,000	18,000	375,210	1,535,538	2,783,812		6,814,943
Transactions with owners:									
- Final dividend @ Rs. 110 per ordinary share for the year ended December 31, 2024	-	-	-	-	-	-	(1,060,924)		(1,060,924)
Profit for the period	-	-	-	-	-	-	1,343,945		1,343,945
Other comprehensive income	-	-	-	-	-	-	-		-
Total comprehensive income for the period	-	-	-	-	-	-	1,343,945		1,343,945
Balance as at June 30, 2025 (Un-audited)	96,448	5,935	2,000,000	18,000	375,210	1,535,538	3,066,833		7,097,964
Balance as at January 01, 2026 (Audited)	**96,448**	**5,935**	**2,000,000**	**18,000**	**375,210**	**1,535,538**	**4,172,049**		**8,203,180**
Transactions with owners:									
- Final dividend @ Rs. 190 per ordinary share for the year ended December 31, 2025	-	-	-	-	-	-	(1,832,504)		(1,832,504)
Profit for the period	-	-	-	-	-	-	2,195,601		2,195,601
Other comprehensive income	-	-	-	-	-	-	-		-
Total comprehensive income for the period	-	-	-	-	-	-	2,195,601		2,195,601
Balance as at June 30, 2026 (Un-audited)	96,448	5,935	2,000,000	18,000	375,210	1,535,538	4,535,146		8,566,277

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Hoechst Pakistan Limited

Unconsolidated Condensed Interim Statement of Cash Flows

For the half year June 30, 2026 (Un-audited)

	June 30, 2026	June 30, 2025
	-------------Rupees in 000-------------	
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	3,698,316	2,345,887
Adjustment for non-cash items:		
Depreciation and amortisation	207,721	163,928
(Reversal) / Allowance for expected credit loss	(11,259)	14,903
Unrealised foreign exchange differences	(1,413)	199,153
Gain on disposal of operating fixed assets - net	(1,438)	(513)
Provision against defined contribution fund	15,383	27,878
Charge for defined benefit plans	26,135	14,830
Provision / (Reversal of provision) against raw and packing material	9,693	(208,294)
Provision / (Reversal of provision) against finished goods	(190,754)	21,283
Interest income on bank deposits	(983)	(1,427)
Fair value gain on remeasurement of mutual funds	(13,644)	(17,984)
Income on mutual funds	(106,502)	(35,883)
Income on Treasury Bills	(10,527)	-
Income on Term Deposit Receipts	(9,693)	-
Income from investment properties	(28,735)	(36,460)
Finance costs	18,543	37,304
Interest expense on lease obligation	25,809	20,864
Settlement adjustment of SIDC liability	(313,212)	-
Remeasurement gain on SIDC liability	(357,244)	-
Finance cost on un-winding of SIDC	13,792	-
	2,969,988	2,545,469
Working capital changes:		
Decrease / (Increase) in current assets:		
Stores and spares	193	(18,273)
Stock-in-trade	1,128,589	1,802,262
Trade debts - net	302,546	186,028
Loans and advances	(225,566)	(180,707)
Trade deposits and short-term prepayments	(303,916)	(43,908)
Other receivables	(14,948)	8,113
	886,898	1,753,515
Increase in current liabilities:		
Trade and other payables	1,229,658	1,245,660
Contract liabilities	67,673	179,824
Cash generated from operations	5,154,217	5,724,468
Finance costs paid	(18,543)	(50,978)
SIDC paid	(151,552)	-
Interest income received	983	1,427
Income tax paid	(1,149,130)	(587,286)
Retirement benefits paid - net	(149,552)	(20,085)
Long-term loans - net	(1,038)	(1,097)
Long-term deposits	9,248	(14,047)
Net cash generated from operating activities	3,694,633	5,052,402
CASH FLOWS FROM INVESTING ACTIVITIES		
Fixed capital expenditure	(507,100)	(1,187,937)
Sale proceeds from disposal of operating fixed assets	34,830	35,709
Investment in subsidiary	(68,940)	(20,000)
Short-term investments made	(13,678,100)	(14,769,941)
Sale proceeds from disposal of short-term investments	12,401,587	13,288,712
Income received from Treasury Bills	10,527	-
Income received from investment properties	28,735	36,460
Net cash used in investing activities	(1,778,461)	(2,616,997)
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividends paid	(1,825,715)	(1,053,068)
Repayment of short term borrowings	-	(1,200,000)
Lease rentals paid	(32,123)	(20,357)
Net cash used in financing activities	(1,857,838)	(2,273,425)
NET INCREASE IN CASH AND CASH EQUIVALENTS	58,334	161,980
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	134,916	119,796
ADJUSTMENT ON INITIAL APPLICATION OF AMENDMENTS TO IFRS 9 AT BEGINNING OF THE PERIOD	35,725	-
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	228,975	281,776

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd)

Annexure B-1

Hoechst Pakistan Limited
Consolidated Condensed Interim Statement of Profit or Loss

For the half year ended June 30, 2026 (Un-audited)

	Half Year Ended		Quarter Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	---------- Rupees in '000 ----------			
REVENUE FROM CONTRACT WITH CUSTOMERS - NET	16,704,273	16,293,561	9,004,797	8,720,068
Cost of sales	(10,092,928)	(10,669,606)	(5,361,129)	(5,781,922)
GROSS PROFIT	6,611,345	5,623,955	3,643,668	2,938,146
Distribution and marketing costs	(2,719,297)	(2,276,861)	(1,449,390)	(1,173,246)
Administrative expenses	(556,696)	(513,596)	(260,777)	(244,332)
Allowance for expected credit loss	11,259	(14,903)	53,305	31,563
Other expenses	(454,215)	(523,508)	(319,728)	(324,471)
Other income	864,269	108,062	776,785	63,940
	(2,854,680)	(3,220,806)	(1,199,805)	(1,646,546)
OPERATING PROFIT	3,756,665	2,403,149	2,443,863	1,291,600
Finance costs	(58,203)	(58,173)	(33,057)	(16,677)
PROFIT BEFORE LEVIES AND INCOME TAX	3,698,462	2,344,976	2,410,806	1,274,923
Levies:				
- Minimum tax differential	-	(110)	-	12,799
- Final tax	-	-	-	696
PROFIT BEFORE INCOME TAX	3,698,462	2,344,866	2,410,806	1,288,418
Income tax - Current	(1,354,525)	(937,681)	(646,945)	(475,623)
- Deferred	(152,637)	(64,151)	(283,460)	(23,008)
	(1,507,162)	(1,001,832)	(930,405)	(498,631)
PROFIT FOR THE PERIOD	2,191,300	1,343,034	1,480,401	789,787
EARNINGS PER SHARE - basic and diluted (Rupees)	227.20	139.25	153.49	81.89

Hoechst Pakistan Limited

Consolidated Condensed Interim Statement of Comprehensive Income

For the half year ended June 30, 2026 (Un-audited)

	Half Year Ended		Quarter Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	Rupees in '000			
PROFIT FOR THE PERIOD	2,191,300	1,343,034	1,480,401	789,787
OTHER COMPREHENSIVE INCOME FOR THE PERIOD				
Exchange differences on translation of foreign operations	(733)	-	(293)	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	2,190,567	1,343,034	1,480,108	789,787

Annexure B-3

Hoechst Pakistan Limited
Consolidated Condensed Interim Statement of Financial Position
As at June 30, 2026

	June 30, 2026	December 31, 2025
	---------------- Rupees in '000	--------------
	(Un-audited)	(Audited)
ASSETS		
NON-CURRENT ASSETS		
Property, plant and equipment	3,090,896	2,581,126
Intangible assets	805,278	806,053
Investment properties	27,129	27,714
Long-term loans	9,502	8,464
Long-term deposits	57,245	66,493
Deferred tax asset - net	393,703	546,340
	4,383,753	4,036,190
CURRENT ASSETS		
Stores and spares	103,170	103,363
Stock-in-trade - net	5,677,852	6,623,493
Trade debts - net	501,036	798,679
Loans and advances	516,877	275,733
Trade deposits and short-term prepayments	568,853	258,581
Other receivables	108,171	69,347
Short-term investments	2,647,567	1,287,435
Income tax recoverable - net	708,023	908,936
Cash and bank balances	291,438	152,872
	11,122,987	10,478,439
TOTAL ASSETS	15,506,740	14,514,629
EQUITY AND LIABILITIES		
SHARE CAPITAL AND RESERVES		
Share capital	96,448	96,448
Reserves	8,455,334	8,097,271
	8,551,782	8,193,719
NON-CURRENT LIABILITIES		
Lease liability	390,271	208,109
Sindh Infrastructure Development Cess (SIDC)	363,789	-
	754,060	208,109
CURRENT LIABILITIES		
Trade and other payables	5,726,360	5,893,022
Contract liabilities	216,157	148,780
Current maturity of long term lease liability	82,405	53,364
Current maturity of SIDC	151,552	-
Unclaimed dividend	24,424	17,635
	6,200,898	6,112,801
CONTINGENCIES AND COMMITMENTS		
TOTAL EQUITY AND LIABILITIES	15,506,740	14,514,629

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd)

Annexure B-4

Hoechst Pakistan Limited

Consolidated Condensed Interim Statement of Changes in Equity

For the half year ended June 30, 2026 (Un-audited)

		Reserves							
		Capital Reserves					Revenue Reserves		
	Issued, subscribed and paid-up share capital	Long-term liabilities forgone	Other capital reserve	Difference of share capital under scheme of arrangement for amalgamation	Share- based payments reserve	Exchange differences on translation of foreign operations	General reserve	Unappropriated profits	Total
	Rupees '000								
Balance as at January 01, 2025	96,448	5,935	2,000,000	18,000	375,210	-	1,535,538	2,783,812	6,814,943
- Final dividend @ Rs. 110 per ordinary share for the year ended December 31, 2024	-	-	-	-	-	-	-	(1,060,924)	(1,060,924)
Profit for the period	-	-	-	-	-	-	-	1,343,034	1,343,034
Other comprehensive income for the period	-	-	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	-	-	-	-	1,343,034	1,343,034
Balance as at June 30, 2025 (Un-audited)	96,448	5,935	2,000,000	18,000	375,210	-	1,535,538	3,065,922	7,097,053
Balance as at January 01, 2026	96,448	5,935	2,000,000	18,000	375,210	-	1,535,538	4,162,588	8,193,719
- Final dividend @ Rs. 190 per ordinary share for the year ended December 31, 2025	-	-	-	-	-	-	-	(1,832,504)	(1,832,504)
Profit for the period	-	-	-	-	-	-	-	2,191,300	2,191,300
Other comprehensive income for the period	-	-	-	-	-	(733)	-	-	(733)
Total comprehensive income for the period	-	-	-	-	-	(733)	-	2,191,300	2,190,567
Balance as at June 30, 2026 (Un-audited)	96,448	5,935	2,000,000	18,000	375,210	(733)	1,535,538	4,521,384	8,551,782

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Annexure B-5

Hoechst Pakistan Limited

Consolidated Condensed Interim Statement of Cash Flows

For the half year June 30, 2026 (Un-audited)

	June 30, 2026	June 30, 2025
	-------------Rupees in 000-------------	
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before income tax	3,698,462	2,344,866
Adjustment for non-cash items:		
Depreciation and amortisation	207,725	163,928
(Reversal) / Allowance for expected credit loss	(11,259)	14,903
Unrealised foreign exchange differences	(1,413)	199,153
Gain on disposal of operating fixed assets - net	(1,438)	(513)
Provision against defined contribution fund	15,378	27,878
Charge for defined benefit plans	26,135	14,830
Provision / (Reversal of provision) against raw and packing material	9,693	(208,294)
(Reversal of provision) / Provision against finished goods	(190,754)	21,283
Interest income	(1,251)	(1,427)
Fair value gain on remeasurement of mutual funds	(24,683)	(17,983)
Income on mutual funds	(106,502)	(35,883)
Mark up income on Treasury Bills	(10,527)	-
Mark up income on Term Deposit Receipts	(9,693)	-
Income from investment properties	(28,735)	(36,460)
Finance costs	18,548	37,414
Interest expense on lease obligation	25,809	20,864
Minimum tax differential	-	110
Settlement adjustment of SIDC liability	(313,212)	-
Remeasurement gain on SIDC liability	(357,244)	-
Finance cost on un-winding of SIDC	13,792	-
	2,958,831	2,544,669
Working capital changes:		
Decrease / (Increase) in current assets:		
Stores and spares	193	(18,273)
Stock-in-trade	1,126,702	1,799,507
Trade debts - net	302,546	186,028
Loans and advances	(241,144)	(186,209)
Trade deposits and short-term prepayments	(303,916)	(43,908)
Other receivables	(14,948)	11,033
	869.433	1.748.178
Increase in current liabilities:		
Trade and other payables	1,206,739	1,247,446
Contract liabilities	67,377	179,905
Cash generated from operations	5,102,380	5,720,198
Finance costs paid	(18,547)	(51,198)
SIDC Paid	(151,552)	-
Interest income received	1,251	1,427
Minimum tax differential paid	-	(110)
Income tax paid	(1,153,667)	(587,128)
Retirement benefits paid - net	(149,552)	(20,085)
Long-term loans - net	(1,038)	(1,097)
Long-term deposits	9,248	(14,047)
Net cash generated from operating activities	3,638,523	5,047,960
CASH FLOWS FROM INVESTING ACTIVITIES		
Fixed capital expenditure	(532,006)	(1,187,937)
Sale proceeds from disposal of operating fixed assets	34,830	35,709
Investment in subsidiary	-	-
Short-term investments made	(13,678,100)	(14,769,941)
Sale proceeds from disposal of short-term investments	12,458,903	13,288,712
Income received from Treasury Bills	10,527	-
Income received from investment properties	28,735	36,460
Net cash used in investing activities	(1,677,111)	(2,596,997)
CASH FLOWS FROM FINANCING ACTIVITIES		
Dividends paid	(1,825,715)	(1,053,068)
Repayment of short term borrowings	-	(1,200,000)
Lease rentals paid	(32,123)	(20,357)
Net cash used in financing activities	(1,857,838)	(2,273,425)
NET INCREASE IN CASH AND CASH EQUIVALENTS	103,574	177,538
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	152,872	119,796
EXCHANGE DIFFERENCES ON TRANSLATION OF FOREIGN OPERATIONS	(733)	-
ADJUSTMENT OF INITIAL APPLICATION OF AMENDMENTS TO IFRS 9 AT BEGINNING OF THE PERIOD	35,725	-
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	291,438	297,334

Hoechst Pakistan Limited
(Formerly Sanofi-Aventis Pakistan Limited)
Plot No. 23, Sector 22,
Korangi Industrial Area,
Karachi 74900, Pakistan

Annexure C

DISCLOSURE FORM
IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company	Hoechst Pakistan Limited
Date of Report	August 20, 2026
Name of Company as specified in the Memorandum of Association	Hoechst Pakistan Limited
Company's Registered Office	Plot 23, Sector 22, Korangi Industrial Area, Karachi-74900
Contact Information	Tel: (021) 35060221-35

Disclosure of material information by listed company in terms of Section 96 and 131:

This is further to our letter dated March 24, 2026 through which we communicated that the Board of Directors of the Company accorded its in-principle approval to the management to evaluate various options for medium-long term strategic expansion of the Company including potential product partnerships, investment into manufacturing assets and acquisition of majority stake in pharmaceutical company either directly or through its subsidiary company(ies).

With this background, please note that the Board of Directors of the Company, in its meeting held on August 20, 2026 has authorized the management to conclude due diligence for the potential acquisition of a pharmaceutical company and to finalize commercial terms and conditions including binding offer(s) and definitive agreement(s) subject to compliance with the applicable laws and fulfillment of applicable corporate and regulatory approvals.

The Board of Directors has authorized its Chief Executive Officer and authorized Director(s), jointly and/or singly to take such necessary steps as may be necessary in accordance with applicable laws including but not limited to finalization of commercial terms, transaction and financing structures.

Pursuant to the requirements of the Securities Act, 2015, the Company has duly caused this form/statement to be signed on its behalf by the undersigned hereunto duly authorized.

For and on behalf of
Hoechst Pakistan Limited

Hoechst Pakistan Limited (Formerly Sanofi-Aventis Pakistan Ltd.)

Syed Muhammad Taha Naqvi
Company Secretary